Sumitomo Pharma Co., Ltd. Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

4506

Pozycja w akcjach #3255
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Cena akcji
$12.08
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$5.42B
Zmiana (1 dzień)
0.52%
Zmiana (1 rok)
0.08%
Kraj
JP
Handel Sumitomo Pharma Co., Ltd. (4506)

Kategoria

Healthcare
Cena 4506 z kapitalizacją rynkową B
Sumitomo Pharma Co., Ltd. Sumitomo Pharma Co., Ltd.
4506
$12.08
Kapitalizacja rynkowa Sumitomo Pharma Co., Ltd.(4506)
Kapitalizacja rynkowa: $5.42B
Na dzień October 2026 spółka Sumitomo Pharma Co., Ltd. ma kapitalizację rynkową wynoszącą $5.42B. Według naszych danych, czyni to Sumitomo Pharma Co., Ltd. 3255th najcenniejszą firmą na świecie pod względem kapitalizacji rynkowej. Kapitalizacja rynkowa to całkowita wartość rynkowa wszystkich wyemitowanych akcji spółki giełdowej i jest powszechnie stosowana do oceny jej wartości.
Historia kapitalizacji rynkowej Sumitomo Pharma Co., Ltd. od 2009 do 2026
4506 w porównaniu do 5 najpopularniejszych stocks
Cena za 4506 Aktywa B Kapitalizacja rynkowa B Wyniki
Sumitomo Pharma Co., Ltd. Sumitomo Pharma Co., Ltd.
$11,518.32 $4.39B
$5.167T +117,553.88%
Sumitomo Pharma Co., Ltd. Sumitomo Pharma Co., Ltd.
$11,178.90 $4.39B
$5.015T +114,086.89%
Sumitomo Pharma Co., Ltd. Sumitomo Pharma Co., Ltd.
$9,158.41 $4.39B
$4.108T +93,448.62%
Sumitomo Pharma Co., Ltd. Sumitomo Pharma Co., Ltd.
$8,698.09 $4.39B
$3.902T +88,746.64%
Sumitomo Pharma Co., Ltd. Sumitomo Pharma Co., Ltd.
$5,995.31 $4.39B
$2.689T +61,139.11%